Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "osteoarthritis (OA)"

Lilly Says New Type of Pain Drug Could Reduce Need for Opioids

Ransdell Pierson  |  May 28, 2016

(Reuters)—Eli Lilly and Co. on Tuesday said it and partner Pfizer Inc. aim to seek approval by 2018 for a new type of pain drug that could be an alternative to opioids for osteoarthritis, chronic back pain and cancer pain. The Indianapolis drugmaker said tanezumab, given by injection every eight weeks, could be a far…

Osteoarthritis Treatments: Monoclonal Antibody Starts Clinical Trial & Fasinumab Promising for Treating Pain

Michele B. Kaufman, PharmD, BCGP  |  May 25, 2016

Recent clinical trials have evaluated the efficacy of GSK3196165, a monoclonal antibody, and fasinumab, a nerve growth factor antibody, in treating patients with osteoarthritis and pain…

Foot Orthoses vs. Rocker-Sole Footwear: Which Treatment Is More Effective for Reducing Pain in First MPT Joint OA?

Arthritis Care & Research  |  May 5, 2016

Foot osteoarthritis (OA) of the first metatarsophalangeal (MTP) joint is thought to have biomechanical factors, but its treatments have not been comprehensively tested in clinical trials. In the first study to explore the efficacy of mechanical interventions, researchers compared the effectiveness of foot orthoses and rocker-sole footwear in reducing pain. Both interventions were effective, but the foot orthoses group wore the intervention for significantly more hours than the footwear group…

Researchers Work to Untangle the Relationship Between Blood Lipids, Bone Health & Diet

Lara C. Pullen, PhD  |  May 2, 2016

A recent editorial examined research findings on how low levels of high-density lipoprotein (HDL) in the blood affect bone health, resulting in cartilage dysfunction and the development of osteoarthritis (OA). Authors note that a high-fat diet in mice with HDL deficiency resulted in OA development; thus, they conclude that in patients with metabolic syndrome, HDL may have a causative relationship to OA…

Combo Drug for Arthritis & Hypertension Meets Goal in Phase 3 Study

Rosmi Shaji  |  December 17, 2015

(Reuters)—Kitov Pharmaceuticals Holdings Ltd. said on Tuesday its lead drug, KIT-302, met the main goal of a late-stage study, reducing pain without increasing the risk of heart diseases in patients with osteoarthritis. Israel-based Kitov says its drug does not need to be labeled with health warnings, but will instead say it reduces the risk of…

Exercise Helps Manage Hip Osteoarthritis Pain

Kathryn Doyle  |  December 12, 2015

(Reuters Health)—Water- or land-based exercise should provide some short-term benefit in pain management for hip osteoarthritis, though there are few well-designed trials testing it, according to a new review. “It is nice to finally have some hip-specific data, as hip and knee osteoarthritis are often grouped together, and it’s almost certain that there are differences…

Vitamin C Derivative Promising Option for OA

Lara C. Pullen, PhD  |  August 24, 2015

New research in mice has found that treatment with a vitamin C derivative can effectively suppress the generation of mitochondrial superoxide, which plays a role in cartilage degeneration and the progression of osteoarthritis…

Envision Arthritis Pathology

Philip G. Conaghan, MB BS, PhD  |  April 1, 2008

MRI advances in RA and OA

Osteoarthritis Quo Vadis

Roland W. Moskowitz, MD  |  March 1, 2008

Our knowledge of OA has progressed far—does a cure lie ahead?

Take the Measure of Osteoarthritis

Nicholas Bellamy, MBChB, MD, MSc, MBA, DSc  |  February 1, 2008

The WOMAC index standardized OA status measurement, as described by its creator

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences